NASDAQ:ARQL ArQule (ARQL) Stock Price, News & Analysis → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Free ARQL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$20.00▼$20.0050-Day Range$20.00▼$20.0052-Week Range$3.15▼$20.45VolumeN/AAverage Volume5.27 million shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ArQule alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About ArQule Stock (NASDAQ:ARQL)ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! ARQL Stock News HeadlinesMarch 22, 2024 | benzinga.comMerck Sharp & Dohme Corp.'s Net WorthJune 30, 2023 | thestreet.comASCO Live Blog: SaturdayApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.May 5, 2023 | marketwatch.com2023 Fibroblast Growth Factor Receptor 2 Inhibitor Market Share and Growth Rate Forecast for 2030April 3, 2023 | finance.yahoo.comWelcome to My Portfolio - Link your brokers or add lotsSeptember 21, 2022 | globenewswire.com40+ Key Companies Actively Working in the Marginal Zone Lymphoma Pipeline Segment | DelveInsight - GlobeNewswireAugust 21, 2022 | streetinsider.comForm SC 13E3 Stealth BioTherapeutics Filed by: Stealth BioTherapeutics Corp - StreetInsider.comJune 30, 2022 | seekingalpha.comMerus Stock: Precision Oncology Pioneer Executes In The Clinic (NASDAQ:MRUS) - Seeking AlphaApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.June 18, 2022 | gurufocus.comAptose Reports Results for the First Quarter 2022 - GuruFocus.comMay 9, 2022 | seekingalpha.comAptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call Transcript - Seeking AlphaMay 9, 2022 | marketscreener.comRENEWABLE ENERGY GROUP, INC. : Other Events (form 8-K) - Marketscreener.comMay 9, 2022 | financialpost.comAptose Reports Results for the First Quarter 2022 - Financial PostApril 26, 2022 | streetinsider.comForm DEF 14A Deciphera Pharmaceutical For: Jun 23 - StreetInsider.comApril 13, 2022 | globenewswire.comBasilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting - GlobeNewswireApril 11, 2022 | marketscreener.comAPTOSE BIOSCIENCES INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.comApril 8, 2022 | streetinsider.comAptose Announces Executive Management Changes - StreetInsider.comMarch 1, 2022 | marketscreener.comWest Pharmaceutical Services : Names President and CEO Eric M. Green as Chair of the Board - Form 8-K - marketscreener.comFebruary 28, 2022 | prnewswire.comWest Names President and CEO Eric M. Green as Chair of the Board - PRNewswireFebruary 15, 2022 | globenewswire.comBasilea to become a leading anti-infectives company backed - GlobeNewswireJanuary 20, 2022 | streetinsider.comHeartFlow Appoints Timothy Barabe to its Board of Directors - StreetInsider.comJanuary 18, 2022 | finance.yahoo.comHeartFlow Appoints Timothy Barabe to its Board of Directors - Yahoo FinanceJanuary 6, 2022 | globenewswire.comBasilea reports on portfolio progress made in 2021 - GlobeNewswireJanuary 3, 2022 | marketscreener.comCuris Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations - marketscreener.comNovember 2, 2021 | investorplace.comSAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher - InvestorPlaceOctober 11, 2021 | finance.yahoo.comBasilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference - Yahoo FinanceSeptember 30, 2021 | marketscreener.comEnlivex Therapeutics : NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON (Form 6-K) - Marketscreener.comSee More Headlines Receive ARQL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArQule and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ARQL CUSIP04269E10 CIK1019695 Webwww.arqule.com Phone781-994-0300FaxN/AEmployees36Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,480,000.00 Net Margins-805.61% Pretax MarginN/A Return on Equity-33.10% Return on Assets-26.87% Debt Debt-to-Equity Ratio0.08 Current Ratio8.27 Quick Ratio8.27 Sales & Book Value Annual Sales$25.76 million Price / Sales93.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book27.78Miscellaneous Outstanding Shares120,873,000Free FloatN/AMarket Cap$2.42 billion OptionableOptionable Beta2.49 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Paolo Pucci (Age 58)CEO & Director Mr. Peter S. Lawrence J.D. (Age 56)Pres, COO, Gen. Counsel & Sec. Dr. Brian Schwartz (Age 57)Chief Medical Officer & Sr. VP Mr. Robert J. Weiskopf (Age 68)CFO, Sr. VP, Principal Accounting Officer & Treasurer Dr. Marc Schegerin M.D.CFO, Head of Strategy & TreasurerKey CompetitorsGeronNASDAQ:GERNAmicus TherapeuticsNASDAQ:FOLDDynavax TechnologiesNASDAQ:DVAXIronwood PharmaceuticalsNASDAQ:IRWDLigand PharmaceuticalsNASDAQ:LGNDView All Competitors ARQL Stock Analysis - Frequently Asked Questions How were ArQule's earnings last quarter? ArQule, Inc. (NASDAQ:ARQL) announced its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $1.20 million. ArQule had a negative net margin of 805.61% and a negative trailing twelve-month return on equity of 33.10%. During the same period last year, the business earned ($0.05) EPS. What other stocks do shareholders of ArQule own? Based on aggregate information from My MarketBeat watchlists, some companies that other ArQule investors own include Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Verastem (VSTM), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Celldex Therapeutics (CLDX), Novavax (NVAX), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE) and CRISPR Therapeutics (CRSP). This page (NASDAQ:ARQL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsThe AI stock to buy right nowStockEarningsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsKeep Your Eyes on This Power-Mad PoliticianAltimetryThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArQule, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
